This site is intended for Healthcare professionals only.
×

Sage Therapeutics gets USFDA nod to Zulresso for treating depression


Sage Therapeutics gets USFDA nod to Zulresso for treating depression

In a company-funded study of new mothers with moderate or severe postpartum depression, half the women given Zulresso had depression end within 2 ½ days, about double the rate of those in a comparison group given dummy treatments.

TRENTON: The U.S. Food and Drug Administration has approved the first drug specifically developed for severe depression after childbirth.

The agency on Tuesday approved Sage Therapeutics’ Zulresso(ZUHL’-ress-oh), an IV drug given over 2 ½ days.

In a company-funded study of new mothers with moderate or severe postpartum depression, half the women given Zulresso had depression end within 2 ½ days, about double the rate of those in a comparison group given dummy treatments.

Read Also: FDA panel recommends Sage’s postpartum depression treatment

Postpartum depression affects about 400,000 American women a year. It’s often treated with antidepressants, though they can take several weeks to help and don’t always work.

Sage said Zulresso will cost $34,000 without insurance, plus costs for the stay in a hospital or infusion centre.

The following two tabs change content below.
Farhat Nasim

Farhat Nasim

Farhat Nasim joined Medical Dialogue as Reporter in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier's College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751


Source: AP
0 comment(s) on Sage Therapeutics gets USFDA nod to Zulresso for treating depression

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted